Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(20):7992–8002. doi: 10.1158/0008-5472.CAN-10-0585

Figure 1. Doclitaxel Suppresses PSA Expression in Human Prostate Tumors.

Figure 1

Panel A reveals the PSA immunoreactivity pattern of prostate tissue array: from the left panel, untreated patients; right, Docetaxel-treated patients. Panel B shows representative images of individual prostate tumor TMAs from untreated control and docetaxel treated prostate cancer patients. Immunostaining for PSA was conducted as described in “Materials and Methods”. Panel C; Quantitative evaluation of PSA expression in tumor epithelial cells in prostate specimens from Docetaxel-treated and untreated prostate cancer patients was determine as described in “Materials and Methods”. * P< 0.01.